Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rosiglitazone × Sarcoma × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2 Gastrointestinal 2 Endocrine 2 Dermatologic 2 Sarcoma 1 Other 1 Lymphoid 1 Head & Neck 1 CNS 1 Breast 1

Conditions

Sarcoma 1 Liposarcoma 1

Interventions

Radiotherapy 124 Cyclophosphamide 124 Temozolomide 108 Doxorubicin 89 Filgrastim 59 Ifosfamide 58 Gemcitabine 51 Etoposide 49 fludarabine phosphate 47 Bevacizumab 47 Imatinib Mesylate 46 Irinotecan 43 pembrolizumab 41 pazopanib 40 Peripheral Blood Stem Cell Transplantation 38 Methotrexate 36 Busulfan 36 Vincristine 35 Magnetic Resonance Spectroscopy 35 Carboplatin 35 Nivolumab 33 Melphalan 33 Cisplatin 33 Surgical Procedures, Operative 32 Radiation 30 Mycophenolic Acid 29 Cyclosporine 29 Blood Specimen Collection 29 Docetaxel 28 Trabectedin 27

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00004180 2023-06-26

Rosiglitazone in Treating Patients With Liposarcoma

Dana-Farber Cancer Institute

Phase 2 Completed

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡